IX vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ORIX Corporation presents a stark contrast between strong valuation and weak fundamental health, highlighted by a critical Piotroski F-Score of 2/9. While the stock is significantly undervalued relative to its Graham Number ($39.02) and Intrinsic Value ($76.99), the low health score suggests deteriorating operational efficiency or financial stability. Strong earnings growth (36.6% YoY) and an exceptionally low forward P/E of 2.77 provide a bullish growth narrative, but these are offset by a bearish technical trend score and poor insider sentiment.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
IX vs JPM: Head-to-Head Comparison
This page compares ORIX Corporation (IX) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.